Mackie upgraded shares of Correvio Pharma (NASDAQ:CORV) from a hold rating to a buy rating in a report published on Friday, MarketBeat reports.

Separately, ValuEngine upgraded shares of Correvio Pharma from a hold rating to a buy rating in a research report on Thursday, September 6th.

Shares of NASDAQ:CORV traded up $0.08 during mid-day trading on Friday, reaching $3.32. The stock had a trading volume of 169,828 shares, compared to its average volume of 171,016. The company has a market capitalization of $140.18 million, a price-to-earnings ratio of -3.69 and a beta of -0.22. The company has a debt-to-equity ratio of 2.71, a current ratio of 4.11 and a quick ratio of 3.49. Correvio Pharma has a twelve month low of $1.29 and a twelve month high of $5.24.

Correvio Pharma (NASDAQ:CORV) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.23). The firm had revenue of $6.18 million during the quarter, compared to analyst estimates of $7.16 million. Correvio Pharma had a negative net margin of 69.75% and a negative return on equity of 230.15%. Equities research analysts expect that Correvio Pharma will post -1.01 earnings per share for the current year.

An institutional investor recently bought a new position in Correvio Pharma stock. Putnam Investments LLC bought a new position in shares of Correvio Pharma Corp (NASDAQ:CORV) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,092,133 shares of the company’s stock, valued at approximately $11,688,000. 45.50% of the stock is owned by institutional investors.

Correvio Pharma Company Profile

Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.

Read More: Price to Earnings Ratio (PE)

Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with's FREE daily email newsletter.